(Q35566908)

8 August 2017

title

Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone (English)

1 reference

8 August 2017

main subject

anti-retroviral agent

0 references

0 references

Joseph L Goulet

4

0 references

David A. Fiellin

object named as

David A Fiellin

8

0 references

Jeanette M. Tetrault

1

object named as

Jeanette M Tetrault

1 reference

8 August 2017

7

Amy C Justice

1 reference

8 August 2017

Janet P Tate

2

1 reference

8 August 2017

Kathleen A McGinnis

3

1 reference

8 August 2017

Lynn E Sullivan

5

1 reference

8 August 2017

Kendall Bryant

6

1 reference

8 August 2017

Veterans Aging Cohort Study Team

9

1 reference

8 August 2017

publication date

28 July 2011

1 reference

Alcoholism: Clinical and Experimental Research

8 August 2017

published in

1 reference

8 August 2017

volume

36

1 reference

8 August 2017

issue

2

1 reference

8 August 2017

page(s)

318-324

1 reference

Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Targeted naltrexone for problem drinkers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Naltrexone for the management of alcohol dependence

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Oral naltrexone maintenance treatment for opioid dependence

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Self-reported antiretroviral therapy in injection drug users.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

A risk-benefit assessment of naltrexone in the treatment of alcohol dependence

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Effects of long-term therapy with naltrexone on body weight in obesity

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Naltrexone: lack of effect on hepatic enzymes.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Development and verification of a "virtual" cohort using the National VA Health Information System.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Alcohol consumption and HIV disease progression: are they related?

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Effect of opioid dependence pharmacotherapies on zidovudine disposition

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Problem drinking and medication adherence among persons with HIV infection

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

[Effect of methadone or naltrexone on the course of transaminases in parenteral drug users with hepatitis C virus infection]

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

Effects of Long-Term Treatment with Naltrexone on Hepatic Enzyme Activity

24 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1530-0277.2011.01601.X

High-Dose Naltrexone and Liver Function Safety

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221963

A controlled trial of naltrexone in obese humans

7 December 2018

1 reference

12 December 2020

Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking

1 reference

12 December 2020

Study of hepatotoxicity of naltrexone in the treatment of alcoholism

1 reference

12 December 2020

Hepatic complications of obesity

1 reference

12 December 2020

10.1111/J.1530-0277.2011.01601.X

Identifiers

DOI

1 reference

8 August 2017

1 reference

8 August 2017

1 reference